Are you navigating life with treatment-resistant rheumatoid arthritis?
If so, you may be eligible for this study which aims to assess a study drug for treatment-resistant rheumatoid arthritis (RA).
What is the Purpose of The Frontier Study?
This study aims to assess the effectiveness of a study drug and how it impacts rheumatoid arthritis symptoms.
You may be eligible to participate in this study if you:
- Live in the United States
- Are between the ages of 18 - 75 years old
- Have a confirmed diagnosis of rheumatoid arthritis
- Have been told by your doctor that your rheumatoid arthritis is refractory*
*‘Refractory’ means your rheumatoid arthritis does not respond to standard treatment options or improve despite trying different medications.
You may not be eligible for this study if you:
- Live outside the United States
- Have other current inflammatory joint disease other than RA
- Have had any type of organ transplant
Other eligibility criteria apply and will be evaluated by a study doctor if you choose to continue with screening for the study.
Why Should I Join the Frontier Study?
Participating in this study may help researchers learn more about rheumatoid arthritis and whether the study drug is a safe and effective treatment option
- By enrolling in this study, you may receive access to physicians with experience managing rheumatoid arthritis.
What Should I Expect?
1. Submit Online Questionnaire
This questionnaire will ask for your contact information and a few questions about your medical history to determine your eligibility. Then, select a time for a short phone call with PatientWing. Submitting the questionnaire is voluntary and does not require a commitment to participate in the study.
2. Speak With PatientWing
PatientWing is helping to identify potential individuals who may be interested in the Frontier Study.
You will have a short call with PatientWing to answer additional questions about your medical history and PatientWing will help collect your medical records.
3. Speak With a Research Site
After your conversation with PatientWing, you will meet the research team who will review your medical records. If the research team thinks you are eligible, they will schedule a screening visit. The research team will provide more information during your conversations with them. No question is a bad question, so please share your concerns with the team!
4. Study Participation
After you've completed the screening period, the research team will notify you about your eligibility. If you are enrolled in the study, you should expect the following:
- You will visit the study site approximately 20 times over 12 months.
- You will have follow-up visits with the study team to investigate your response to the study drug.
Participation in this study will not come at an additional cost to you. Reasonable expenses such as travel and parking are reimbursed within reasonable limits.
Frequently Asked Questions
How do I get started?
Fill out the questionnaire and provide basic information to express interest in the study. You can also email studies@patientwing.com or call/text: 213-459-2979.
How is PatientWing involved in this clinical study process?
We partner with study sponsors to match individuals with clinical studies. Our dedicated team provides clear information about available studies, connects you with research sites, and ensures you have the resources and guidance you need at every step. We are here to support your journey with clinical research!
How will the study drug be taken?
The study drug will be given as subcutaneous injection once a week.
How often do I need to visit the research site?
You will have 20 visits to the research site during the study period.
How long will the study take place?
Your participation may be about 13 months.
Is there a chance I will receive a placebo?
No, this study does not have a placebo. You will receive the study drug, blinatumomab, if you participate in the study.